Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol

We investigated the clinical response of chronic heart failure patients with beta(2)-adrenergic receptor Gln(27)-->Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate,...

Full description

Saved in:
Bibliographic Details
Published in:Basic & clinical pharmacology & toxicology 2009-05, Vol.104 (5), p.374-378
Main Authors: Troncoso, Rodrigo, Moraga, Francisco, Chiong, Mario, Roldán, Juan, Bravo, Roberto, Valenzuela, Rodrigo, Díaz-Araya, Guillermo, del Campo, Andrea, Sanhueza, Carlos, Rodriguez, Andrea, Vukasovic, José Luis, Mellado, Rosemarie, Greig, Douglas, Castro, Pablo F, Lavandero, Sergio
Format: Article
Language:English
Subjects:
Adrenergic beta-2 Receptor Antagonists
Adrenergic beta-Antagonists - administration & dosage
Adrenergic beta-Antagonists - pharmacology
Adrenergic beta-Antagonists - therapeutic use
Carbazoles - administration & dosage
Carbazoles - pharmacology
Carbazoles - therapeutic use
Chronic Disease
Down-Regulation
Female
Heart Failure - drug therapy
Heart Failure - genetics
Heart Failure - metabolism
Heart Failure - physiopathology
Humans
Male
Malondialdehyde - blood
Middle Aged
Oxidative Stress - drug effects
Pharmacogenetics
Polymorphism, Genetic
Propanolamines - administration & dosage
Propanolamines - pharmacology
Propanolamines - therapeutic use
Receptors, Adrenergic, beta-2 - genetics
Ventricular Function, Left - drug effects
Ventricular Function, Left - physiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the clinical response of chronic heart failure patients with beta(2)-adrenergic receptor Gln(27)-->Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu(27)beta(2)-adrenergic receptor allele. There were however, no significant changes in patients with the Gln(27)beta(2)-adrenergic receptor variant.
ISSN:1742-7843